Cannabis-Derived Sativex for MS-Related Spasticity Reported to Be Effective and Safe

November 1, 2015 /
Alternative therapies and devices for Multiple Sclerosis (MS)
Spray is only pharmaceutical derived from cannabinoids approved to treat spasticity symptoms in multiple sclerosis

<span class="entry-title">Cannabis-Derived Sativex for MS-Related Spasticity Reported to Be Effective and Safe</span><span class="entry-subtitle">Spray is only pharmaceutical derived from cannabinoids approved to treat spasticity symptoms in multiple sclerosis</span>

Barcelona, Spain-based, global pharma firm Almirall presented new clinical evidence at the31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) — held in Barcelona October 7–10, 2015 — supporting the efficacy of its Sativex product, currently the only pharmaceutical medicine derived from cannabinoids to treat spasticity symptoms in multiple sclerosis (MS). Experts attending discussed various aspects of the disease, including spasticity’s impact on patients’ quality of life, and the specifics of its treatment with Sativex.


Read on »

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MS Views and News helps to provide information for all affected by MS
Keep up to date with the news and information we provide 
by signing up by clicking here
.===================================
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews

Stay informed with MS news and information - Sign-up here

For MS patients, caregivers or clinicians, Care to chat about MS? Join Our online COMMUNITY CHAT

Share:

Categories

Latest Blog Posts